medications like semaglutide and Tirzepatide are not just for diabetes and weight loss! Major clinical trials like PIONEER 6 and SUSTAIN 6 have shown that Semaglutide also significantly reduces the risk of Weight-loss injections are dominating the

That means that obesity may contribute to depression, and depression may contribute to obesity

Clinical trials conducted during the drug's development and post-marketing surveillance data have not established a direct causal relationship between semaglutide administration and musculoskeletal pain in the lumbar region

Liver function has minimal impact on semaglutide half-life since the liver isnt the primary organ for its elimination

It binds to GLP-1 receptors found on: Pancreatic -cells Stimulates glucose-dependent insulin secretion Pancreatic -cells Suppresses glucagon release during hyperglycemia Hypothalamic satiety centers Reduces appetite and food intake Gastrointestinal tract Delays gastric emptying, enhancing satiety This multi-site activity leads to improved glycemic control, reduced body weight, and cardiovascular benefits

These medications support weight loss by activating appetite-regulating pathways in the brain, slowing gastric emptying, and enhancing glucose-dependent insulin secretion

Collectively, these intertwined metabolic, inflammatory, and hemodynamic processes underpin the development and progression of DKD (Fig